Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | LIPC | P11150 | 4/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132766 | 0.94 | HSD17B10 (0.49) | JAK2LRRK2ERN1TLR8TLR7 | |
| SCHEMBL3338474 | 0.90 | HPGD (0.44) | TLR8TLR7HPGDCSF1RMEN1 | |
| SCHEMBL3335847 | 0.88 | HPGD (0.43) | JAK2HPGDMEN1KMT2A | |
| SCHEMBL4355847 | 0.80 | JAK2 (0.56) | JAK2ERN1TLR8TLR7HPGD | |
| SCHEMBL3336523 | 0.78 | IP6K1 (0.47) | ATMRXFP1 | |
| SCHEMBL3336495 | 0.78 | MKNK1 (0.42) | HPGDMEN1KMT2AATMPIK3CA | |
| SCHEMBL3338819 | 0.78 | CYP3A4 (0.47) | LRRK2ERN1HPGDMEN1KMT2A | |
| SCHEMBL3336047 | 0.77 | RXRA (0.38) | JAK2ATM | |
| SCHEMBL3335650 | 0.77 | HPGD (0.50) | TLR8TLR7HPGDHRH3CSF1R | |
| SCHEMBL5129519 | 0.76 | MGLL (0.40) | LRRK2TLR8TLR7HPGDCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | JAK2 1107/4885LRRK2 3408/4885ERN1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.